Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases

被引:104
作者
Chen, Hongjie [1 ]
McGowan, Eileen M. [2 ]
Ren, Nina [3 ]
Lal, Sara [2 ]
Nassif, Najah [2 ]
Shad-Kaneez, Fatima [2 ]
Qu, Xianqin [2 ]
Lin, Yiguang [2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China
[2] Univ Technol Sydney, Sch Life Sci, Broadway, NSW 2007, Australia
[3] Guangdong 2 Prov Peoples Hosp, Guangdong Online Hosp Clin, Guangzhou, Guangdong, Peoples R China
关键词
Nattokinase; natto; cardiovascular disease; antithrombotic agents; antihypertensive drugs; atherosclerosis;
D O I
10.1177/1177271918785130
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cardiovascular disease (CVD) is the leading cause of death in the world and our approach to the control and management of CVD mortality is limited. Nattokinase (NK), the most active ingredient of natto, possesses a variety of favourable cardiovascular effects and the consumption of Natto has been linked to a reduction in CVD mortality. Recent research has demonstrated that NK has potent fibrinolytic activity, antihypertensive, anti-atherosclerotic, and lipid-lowering, antiplatelet, and neuroprotective effects. This review covers the major pharmacologic effects of NK with a focus on its clinical relevance to CVD. It outlines the advantages of NK and the outstanding issues pertaining to NK pharmacokinetics. Available evidence suggests that NK is a unique natural compound that possesses several key cardiovascular beneficial effects for patients with CVD and is therefore an ideal drug candidate for the prevention and treatment of CVD. Nattokinase is a promising alternative in the management of CVD.
引用
收藏
页数:8
相关论文
共 69 条
[1]  
Ahmed H. H., 2013, WJPPS, V3, P876
[2]  
Ahn Y-J, 2015, STROKE, V46
[3]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[4]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5]   Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer's disease by fermented soybean nanonutraceutical [J].
Bhatt, Prakash Chandra ;
Pathak, Shruti ;
Kumar, Vikas ;
Panda, Bibhu Prasad .
INFLAMMOPHARMACOLOGY, 2018, 26 (01) :105-118
[6]  
Chang CH, 2010, ACTA MED OKAYAMA, V64, P399
[7]   Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds [J].
Chang, Yung-Yee ;
Liu, Jia-Shou ;
Lai, Shung-Lon ;
Wu, Hsiu-Shan ;
Lan, Min-Yu .
INTERNAL MEDICINE, 2008, 47 (05) :467-469
[8]   Nattokinase: production and application [J].
Dabbagh, Fatemeh ;
Negahdaripour, Manica ;
Berenjian, Aydin ;
Behfar, Abdolazim ;
Mohammadi, Fatemeh ;
Zamani, Mozhdeh ;
Irajie, Cambyz ;
Ghasemi, Younes .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2014, 98 (22) :9199-9206
[9]  
Duan Z., 2003, ACTA NUTRIMENTA SIN, V26, P296
[10]  
Duan ZhiBian, 2004, Acta Nutrimenta Sinica, V26, P296